Overview

* Janux Q3 net loss narrows to $24.3 mln from $28.1 mln in 2024

* Research and development expenses rise to $34.6 mln from $18.6 mln in 2024

* Company holds $989 mln in cash and investments at end of Q3 2025

Outlook

* Company expects updates on JANX007 and JANX008 in Q4 2025

* Janux maintains strong cash position to support clinical programs

Result Drivers

* R&D EXPENSES INCREASE - R&D expenses rose to $34.6 mln from $18.6 mln in 2024, reflecting increased investment in clinical programs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $10 mln

Collabor

ation

Revenue

Q3 Net -$24.31

Income mln

Q3 Basic -$0.39

EPS

Q3 $45.25

Operatin mln

g

Expenses

Q3 -$35.25

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Janux Therapeutics Inc ( JANX ) is $74.00, about 62.8% above its November 5 closing price of $27.54

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)